Designing a Fair, Motivating Profit Split with Doctors, Clinics, and Brands

In April 2023, I went to Hangzhou to talk with a private respiratory clinic about carrying our nasal inhalation smoking-cessation aid in-store. The clinic's legal representative was refreshingly blunt: a suggested retail price (RSP) of 398 RMB per unit, a 45% sales commission for the clinic, and we would handle supply, training, customer complaints, and after-sales reshipment. At the time I ran the numbers: our full cost from factory to channel (including packaging, testing, logistics, and an after-sales reserve) was roughly 95–110 RMB, so 45% meant the clinic would take about 179 RMB per unit, and our margin still looked like 100-plus RMB. But I had not accounted for three things: the clinic wanted 60-day payment terms, unconditional returns and exchanges, and each individual doctor also wanted a separate "referral incentive" carved out.

The contract never got signed — the clinic was already arguing internally: the director wanted the institution to keep the bigger share, the consulting doctors felt the patients were brought in by their own persuasion, and we on the brand side had realized that once the individual doctors took another 8%–12%, we would be left with little more than a handling fee per unit. That collaboration dragged on for 11 weeks and finally fell through, which was the right outcome. The plan was only "generous" on the surface; in essence it was shoving every uncontrollable cost onto the supplier while stirring measurable contributions and unmeasurable trust into a single pot.

Since then I have also negotiated with individual doctor studios, the smoking-cessation corners of dental clinic chains, and co-branding campaigns with two adjacent-track brands. After stepping into enough pits, my view has hardened: fairness is not a 50/50 split, and incentives do not mean bidding the percentage up to the ceiling; fairness means every contribution can be explained, and incentives mean those who can do more can take more — and the accounts always reconcile.

Section I. Three Types of Partners, Completely Different Contribution Structures

Many people run a single split table for all partners: doctors 20%, clinic 20%, brand 60%. It looks neat on paper and is guaranteed to break the moment it touches the ground.

Individual doctors (especially multi-site practitioners and those running studios)

What is truly scarce is the endorsement of trust, and the face-to-face conversation. The patient is not buying a box; they are buying "this doctor thinks you can give it a try." Their contribution is heavy on the conversion step and low on inventory and floor space. Doctors, generally, don't want to hold stock; what they deeply care about is settlement per closed deal, payment speed, and not eating returns.

Clinic / outpatient institution

Its contribution is floor space, front-desk scripts, the return-visit flow, the invoicing entity, and the first line of customer service and complaints. Institutions pay rent, salaries, and run systems. They care more about the whole store's gross margin, average ticket and add-on sales, and whether nurses' hours are being used well. Institutions negotiate on "shelf position + sell-through + return rules," not on sentiment.

The brand side (you, or the co-brand partner)

Its contribution is product compliance and quality, the supply chain, training materials, the customer-acquisition engine (paid media or content), brand equity, and the after-sales backstop. If you also run online consultations and repurchase reminders, you are already playing in the "service layer" — don't book yourself as just a vendor that pockets the gap between two shipment prices.

Among healthcare partnerships, a few distribution philosophies circulate: equal split, production-based, and hybrid. In the private-medical world there is also the "build-operate-transfer" idea — professional service income goes to the professional side, while premises, equipment, and operations income goes to the institution side. In referenced cases, long-term equipment or center collaborations even split profits with the hospital at a higher rate. For a consumer product plus smoking-cessation intervention like ours, we don't need to copy hospital equipment contracts, but we can learn the lesson: price "the professional action" and "the channel action" apart, rather than folding both into one unwieldy percentage.

Section II. Contribution Assessment: First a Checklist, Then the Talk about Percentages

The first page I bring to a partnership meeting is not a commission table but a contribution checklist. Each side writes its own; then we compare.

My principle: what can be quantified gets negotiated with numbers; what cannot gets priced as a defined "service package"; never funnel all of it through a single sales-commission percentage.

Example: a doctor's in-person assessment plus 15 minutes of guidance is a service, payable either as a fixed per-case fee (say 50–80 RMB per case, paid by the patient or carved out of the project package) or as a "post-deal service subsidy." Clinic display and invoicing, by contrast, fits better into the supply-discount or institution-margin space (supply price at 55–65% of retail, leaving the clinic a clean 35–45% margin, instead of stacking another ambiguous "commission" layer). The brand side locks in the supply margin, an after-sales reserve (in my case, I always set aside 3–5% of sales for complaints and reshipments), and — in co-branding — trademark and content-license fees.

In the January 2024 negotiation with a dental chain in Shenzhen, we separated "the doctor's one-sentence chairside recommendation" from "the nurse completing the records and follow-up": the doctor was paid 40 RMB per valid close (patient contact info collected and product activated within 7 days), the nursing team's quarterly bonus was tied to the 30-day follow-up completion rate, and the institution took its margin in the supply line — no second-layer sales commission. In the first three months, across 6 stores, 187 units sold, with 11 returns (about 5.9%), and the doctors' "I can't track this" complaints dropped from several per week to nearly zero. Not because the percentage was raised — because the numbers finally add up.

Section III. Three Broken Models (I Have Paid Tuition on Each)

3.1 A pure high-percentage sales commission

"Take 50%, we take 50%, all in it together." Sounds fair, but actually it fuses returns, advertising fees, payment processing fees, and giveaways into a single pot. At reconciliation, the fight is always about how "net" is defined: by list price, by amount actually paid, or after platform coupons are deducted?

A WeChat community co-brand burned me in 2022: we split 50/50 by GMV, the other party flooded the top line with heavy coupons, the actual collection was only 62% of the list price — and I still had to ship the goods. "The partnership is booming" on paper; cash flow was negative.

Lesson: the contract must state the commission base = net actually received − refunds − the agreed post-sales reserve, and set a minimum settlement price per unit.

3.2 A pure fixed slot fee / entry fee

The clinic collects 3,000–8,000 RMB per month for the shelf position, whether it sells one or none. With no sell-through incentive, the goods become window decoration. It fits only a short-term brand move (one "famous clinic endorsement" photo shoot), not the stage where you need sales volume.

3.3 Oral "friendship price"

"Start first, settle at the end of the month." In the medical periphery this is most dangerous. People transfer, department heads rotate, and the oral promise of the previous holder evaporates. With no order number, no record of patient consent, no invoice trail — you either blow up the relationship or swallow the loss.

Section IV. My Default "Fair and Motivating" Structure

Not the only truth, but the default template I converged on across the pilots of 2023–2025.

4.1 Lock the price anchors first

Set the suggested retail price (RSP) and a lowest allowed transaction price. Example: RSP 398 RMB, uniform online and offline; promotions may not go below 349 RMB without the brand's written consent. Discount chaos punches straight through every commission structure.

4.2 Institutions: live off the "goods-pool margin", not a muddled commission

• Supply price = RSP × 58–65% (depending on whether shipping and training are included)
• The institution's visible gross margin is around 35%–42%
• Stocking: first order small (10–20 kits per store), replenish only when sold; slow stock beyond 90 days allows one negotiated exchange, with the loss split equally or attributed by liability.

This way the institution's incentive is "sell more, turn faster," not endless debate over "does the commission include freight."

4.3 Doctors: paid for "verifiable services", not a naked sales percentage

Two models I can accept:

• Service-fee mode: the patient purchases a bundle of "assessment + guidance + 14-day follow-up"; the physician/team receives an explicit share of the package (e.g., package 199 RMB, physician labor 100–120 RMB), and the product itself is billed separately.
• Piece-rate mode: only an "effective referral" is paid — the definition is hard-coded: deal closed + first-use teaching completed + contact info left in the system. Fixed unit value, settled monthly, with a cap against volume-stuffing (example: max N units per doctor per month, which requires review).

We deliberately avoid the "percentage of drug/device sales paid to the doctor" design. Medical aesthetics and platform-revenue-sharing businesses have tightened scrutiny of the tax, labor, and benefit-transfer boundaries year after year; and even though a cessation aid mostly travels the consumer path, the messaging must never read as "buying referrals," and the money must flow through a service/labor agreement or corporate settlement — never a private transfer.

4.4 Co-brand: "goods margin + brand licensing + joint ad spend"

In co-brand I insist on three separate revenue lines:

1. Supply margin (your bread and butter).

2. Trademark and co-brand package licensing (one-off or annual, from a few thousand to tens of thousands of RMB depending on scale).

3. Joint advertising spend: split AA or by cost per lead.

When I co-branded with a content-facing brand in September 2024, they first asked for 30% of sales as a "brand share." I refused and instead offered: a supply price 8 points lower, a 20,000 RMB/quarter co-brand license fee, and advertising spend split 50/50. In the end they promoted even more enthusiastically — because a license fee is certain income; they no longer had to gamble on our return rate.

4.5 Ladders: only "net-effective" earns

When quarterly net-effective volume (closed orders − returns − bogus orders) hits a tier, the institution or the doctor team receives a rebate — rather than raising the base percentage from the first unit.

Sample (scalable by size):

• 0–50 kits: no extra rebate
• 51–120 kits: 3% of net sales rebate per quarter
• 121 kits and above: 5%

Offset against the next quarter's goods payment. This pushes the operator to work for "net" volume, not volume that can be returned later.

Section V. Long-Term Mechanisms: The Five Rules That Matter More Than the Ratio

5.1 Reconciliation rhythm and data ownership

My standing rule: provide the sales detail within T+7 (data de-identified), monthly reconciliation, quarterly written sign-off. Ownership and allowed uses of sensitive information such as patients' phone numbers go into an appendix. No line-item detail, no incentive pay — that's the iron rule. Half of why that Hangzhou deal died was the other party insisting, "totals only, no line items."

5.2 Probation and exit

Every new partnership starts with a 90-day trial period: if the minimum sell-through is not reached (e.g., 5 kits per store per month on average), either side may exit, with the remaining stock repurchased or exchanged as agreed. On exit, each side stops using the other's trademark and named-doctor endorsements, and the take-down deadline (say, 15 business days) is written into the contract.

5.3 Price and cost triggers

When raw material, testing, or logistics costs swing more than 8%, or platform fee policies change, either side may reopen pricing: if no agreement is reached within 30 days, the old price applies until the existing inventory is cleared, and the relationship then ends. Avoid "the market has moved but the price stays frozen for 3 years."

5.4 Exclusivity is bought, not begged

If the clinic wants regional exclusivity, that is fine — but with a minimum purchase or a minimum net sales volume. Exclusivity without volume only walls off other possibilities for your partner while you starve for lack of volume.

5.5 Compliance messaging and adverse events

Training material is unified: never promise "guaranteed to quit", never disparage legitimate pharmacological approaches, never imply the product replaces the doctor's advice. Adverse events or serious complaints must be communicated to both sides within 24 hours — as must who speaks publicly and who pays for the correction statement; write all of it down in advance.

Public discussions in medical partnerships usually name equal / production-based / hybrid; equipment collaborations emphasize long-term contracts and profit sharing; platform–doctor splits always circle back to tax and compliance. For a smoking-cessation aid, my translation is: use contract language to separate labor from goods, use operating language to chase net-effective volume and follow-up, and use brand language to keep public claims in check.

Section VI. When "Feels Fair" and "Incentive" Fight: Whose Side to Take

In February 2025, a doctor team at a Chengdu clinic was performing brilliantly. The clinic felt the doctors were taking too much and proposed cutting the piece rate from 40 RMB to 25 RMB, with the difference returning to the institution. That very evening, the doctors stopped recommending the product, and weekly sell-through dropped from 14 kits to 2.

When I stepped in, I didn't sweeten the pot or raise the total budget — I just laid out the numbers:

• Institution margin: roughly 130–150 RMB per kit under the supply structure
• Doctor piece rate 40 RMB: about 25%–30% of the institution's margin, which is what buys the conversion
• Nurse follow-up incentive: tied to completion rate, average less than 300 RMB per person per month

The final scheme: keep the piece rate at 40 RMB, but tighten the definition of "effective" (the teaching check-in must be completed); the clinic gets an added "quarterly sell-through bonus" tied to the store's overall margin; and the brand contributes one free in-depth training session. All three parties felt that they had not been taken advantage of, and weekly sell-through returned to double digits within two weeks.

In my personal view: most distribution conflicts are not about two points of percentage difference; they are about someone feeling their contribution is invisible at the table. Making the invisible contribution visible again costs less than simply paying more.

Section VII. When I Prefer Not to Partner at All

• Demands "guaranteed cure" or "unlimited, no-questions refunds," yet refuses follow-up data-sharing and shared responsibility
• Insists on paying individual doctors a high percentage in cash, refusing official-route settlement with full documentation
• Cuts prices, diverts goods across regions, or advertises with fabricated cure screenshots
• Won't even accept a minimum sell-through during the 90-day trial, yet demands exclusivity
• Treats your after-sales as their free customer-service center and deflects complaints back at you

Losing an extra channel for a short time is no disaster; the true disaster is a channel with a high split, high returns, and high reputational risk that burns through margin and brand together.

Section VIII. The Checklist That Goes Straight into the Contract Appendix

1. RSP, floor price, supply price — and whether prices include tax and shipping

2. Definition of the commission/rebate base (net receipts)

3. Trigger conditions and caps for doctor/nurse incentives

4. Return-rate thresholds (e.g., over 8% triggers a business review; over 12% may pause supply)

5. Reconciliation date, objection window (e.g., 5 business days), payment date

6. Data and material ownership, take-down deadlines

7. Trial period, exclusivity terms, exit, and inventory handling

8. Messaging red lines and the adverse-event procedure

Percentages are negotiable; definitions must not be. The moment definitions blur, whatever you call "fair" turns, by month two, into mutual suspicion.

If you are building a smoking-cessation aid or a similar health consumer product, here is the blunt lesson I paid three years to learn: the high percentage a partner asks for is often an insurance premium for their own poorly managed internal interests; your job is not to raise the price to buy peace, but to split the contributions apart, write the net numbers in stone, and tie the incentives to verifiable actions. The partnership that works this way is rarely the one with the highest commission, but it is the one that survives the longest and reconciles most painlessly. Fairness lives on the ledger, motivation lives in behavior — align the two, and the margin holds.